Clinical Trial Update: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update evaluating rivaroxaban versus aspirin for thromboprophylaxis in relapsed or progressive multiple myeloma (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Aspirin (Aspirin)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2, Phase 3 | Status: UNKNOWN